People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arpeggio Biosciences, Inc. | — | Biotech / Pharma | Series B | $46.4M | $80.7M | 2025 |
Samuel G. Kintz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Samuel G. Kintz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy G. Read | 1 | 1 |
| Laura G. Norris | 1 | 1 |
| David G. Allison | 1 | 1 |
| Joseph G. Azofeifa | 1 | 1 |
| Mira G. Chaurushiya | 1 | 1 |
| Aaron G. Royston | 1 | 1 |
| Amit G. Mehta | 1 | 1 |
| Eric G. Martin | 1 | 1 |
| Joe G. McMahon | 1 | 1 |
| Daniel G. Weaver | 1 | 1 |
| Robin D. Dowell-Deen | 1 | 1 |
| Laura D. Norris | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.